Templeton questions AsiaPharmÆs financial results

Templeton, a minority shareholder of AsiaPharm, is opposing a S$357.4 million management buyout offer for the Chinese pharmaceutical company and says the latest fourth quarter results are crucial in assessing the offer.

Quick Poll

Which risk do you perceive as being the most significant for EM investors today?

Previous polls ››

September 2016 Magazine
AsianInvestor Magazine

What's in this issue

Expanding ESG in Asia
Q&A: Jupai Holdings
The Brexit fallout for fund managers
Chinese hedge funds step offshore